Trial results detailing the efficacy and safety of guselkumab for patients with moderately to severely active Crohn's disease, as evaluated in the GALAXI-2 and GALAXI-3 trials, were published on January 1, 2025. This publication provides insights into both intravenous induction and subcutaneous maintenance therapy regimens.
Background
The publication concerns guselkumab (Tremfya), a drug investigated for the treatment of Crohn's disease, a chronic inflammatory condition affecting the gastrointestinal tract. The GALAXI program explored its use in patients with moderately to severely active disease, aiming to understand its potential as a therapeutic option.
Trial design
The GALAXI-2 and GALAXI-3 studies investigated guselkumab in participants with moderately to severely active Crohn's disease. The trials evaluated an intravenous induction regimen followed by subcutaneous maintenance therapy to assess the drug's performance over time in managing the condition.
Key results
The published findings detail the efficacy and safety profile of guselkumab for patients with Crohn's disease. The study assessed both intravenous induction and subcutaneous maintenance therapy, providing comprehensive data on its performance across different treatment phases.
What this means
The publication of these results provides detailed information on the efficacy and safety of guselkumab for clinicians and researchers treating moderately to severely active Crohn's disease. This data contributes to the understanding of guselkumab's role in both the initial and ongoing treatment phases for this chronic inflammatory condition.
Source
The information for this article is based on a publication in PubMed on January 1, 2025. The publication is titled "Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48- (Lancet)" and is available on pubmed.ncbi.nlm.nih.gov.